

ASX Release

4th January 2016

PharmAust Featured on *The RedChip Money Report* Airing on Bloomberg Network

PharmAust Limited ("PharmAust") (ASX: PAA) is pleased to report that its Executive Chairman, Dr. Roger Aston, was recently interviewed on *The RedChip Money Report* television program. The interview was aired on the weekend of 2nd and 3rd January on Bloomberg Australia, at 5:30 p.m. AET, and Bloomberg Latin America, Saturday, January 2, at 10:00 a.m. and 10:30 a.m. local time.

The interview segment can be viewed on the PharmAust website – www.pharmaust.com

"The RedChip Money Report" delivers insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews with executives of public companies. The show is hosted by Dave Gentry, a leading authority on small-cap stocks and the author of *Small Stocks, Big Money*, published by Wiley Finance. Gentry has made multiple guest appearances on both CNBC and Fox Business News.

About PharmAust Ltd.

PharmAust Limited specializes in the relaunch of existing marketed products for oncology applications making the whole development, regulatory, and commercialization process much faster. Its pipeline includes human and veterinary proprietary medicines to treat cancer. PharmAust has two key strategic alliances with major pharmaceutical companies and products about to enter Phase II trials. These products target substantial multi-billion dollar markets. In addition, PharmAust's wholly-owned subsidiary, Epichem Pty Ltd, generates sales of around US \$1.7M per annum from sales of products and contract research to the pharmaceutical industry. Epichem also facilitates the generation of new IP by synthesizing similar drug formulations for projects within the Company.

For further details please contact:

Dr. Roger Aston
Executive Chairman
Tel: 0402 762 204
rogeraston@pharmaust.com

Dave Gentry
President, RedChip Companies
Tel: 1-407-644-4256, ext. 104
dave@redchip.com